ZA888978B - Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension - Google Patents

Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension

Info

Publication number
ZA888978B
ZA888978B ZA888978A ZA888978A ZA888978B ZA 888978 B ZA888978 B ZA 888978B ZA 888978 A ZA888978 A ZA 888978A ZA 888978 A ZA888978 A ZA 888978A ZA 888978 B ZA888978 B ZA 888978B
Authority
ZA
South Africa
Prior art keywords
interleukin
carboxylterminal
immobilized
extension
immobilized interleukin
Prior art date
Application number
ZA888978A
Other languages
English (en)
Inventor
Yuan Lin De Vries
Lin De Vries Yuan
Richard John Robb
John Robb Richard
Paul Simon
Simon Paul
Charles Thayer White
Thayer White Charles
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of ZA888978B publication Critical patent/ZA888978B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA888978A 1987-12-04 1988-11-30 Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension ZA888978B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12893187A 1987-12-04 1987-12-04

Publications (1)

Publication Number Publication Date
ZA888978B true ZA888978B (en) 1990-07-25

Family

ID=22437677

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA888978A ZA888978B (en) 1987-12-04 1988-11-30 Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension

Country Status (11)

Country Link
EP (1) EP0319012A3 (fr)
JP (1) JPH02300A (fr)
KR (1) KR890009978A (fr)
AU (1) AU2635088A (fr)
DK (1) DK673788A (fr)
FI (1) FI885628L (fr)
HU (1) HUT50506A (fr)
IL (1) IL88565A0 (fr)
NO (1) NO885389L (fr)
PT (1) PT89121A (fr)
ZA (1) ZA888978B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229272A (en) * 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
JPH04503607A (ja) * 1989-02-24 1992-07-02 イムノセラピューティックス・インコーポレイテッド 固定化サイトカイン類
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US6955915B2 (en) 1989-06-07 2005-10-18 Affymetrix, Inc. Apparatus comprising polymers
US6919211B1 (en) 1989-06-07 2005-07-19 Affymetrix, Inc. Polypeptide arrays
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
EP0406857B1 (fr) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Protéines et leur production
FR2653020B1 (fr) * 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
EP0537229A1 (fr) * 1990-07-05 1993-04-21 Akzo Nobel N.V. Conjugues de toxine destines a des recepteurs
FR2666898A1 (fr) * 1990-09-18 1992-03-20 Toledano Jacques Dispositif et procede de dosage rapide de recepteurs membranaires ou de leurs ligands.
US6072039A (en) * 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
US5635597A (en) * 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
FR2764988B1 (fr) * 1997-06-20 1999-07-23 Bio Merieux Compose conjugue, reactif et kit le contenant, et utilisations dans un procede de fixation d'un materiel biologique
PT1037927E (pt) 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
EP1228214A2 (fr) 1999-11-12 2002-08-07 MERCK PATENT GmbH Formes d'erythropoietine dotees de proprietes ameliorees
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
JP5390055B2 (ja) 2000-06-29 2014-01-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
HUP0303428A2 (hu) 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
WO2002079415A2 (fr) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reduction de l'immunogenicite de proteines de fusion
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
AU2002346150B2 (en) 2001-07-03 2007-07-19 Jms Co., Ltd. Blood dialysis apparatus having convenient controlling unit
FR2832508A1 (fr) * 2001-11-21 2003-05-23 Bio Merieux Procede d'obtention d'une phase de capture et d'une phase de detection d'un materiel biologique cible et utilisation dans des tests elisa
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
SI2573166T1 (sl) 2004-02-26 2016-09-30 Immunovative Therapies, Ltd. Metode za pripravo T-celic za celično terapijo
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
CN100391726C (zh) * 2006-04-28 2008-06-04 江阴市万事达液压机械有限公司 缸体破碎机
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
PH12013502252B1 (en) 2011-05-03 2018-09-21 Immunovative Therapies Ltd Induction of il-12 using immunotherapy
KR102202460B1 (ko) 2011-05-03 2021-01-14 이뮤노베이티브 테라피스, 엘티디. 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법
CA3106520A1 (fr) * 2018-07-13 2020-01-16 Il-2Rx, Inc. Composes, compositions, methodes et utilisations pour traiter le cancer et des troubles immunologiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (fr) * 1983-08-10 1985-02-28 Amgen Expression microbienne de l'interleukine ii
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide

Also Published As

Publication number Publication date
FI885628A0 (fi) 1988-12-02
AU2635088A (en) 1989-06-08
FI885628A7 (fi) 1989-06-05
HUT50506A (en) 1990-02-28
DK673788D0 (da) 1988-12-02
IL88565A0 (en) 1989-07-31
NO885389D0 (no) 1988-12-02
KR890009978A (ko) 1989-08-05
DK673788A (da) 1989-06-05
EP0319012A2 (fr) 1989-06-07
EP0319012A3 (fr) 1990-05-16
JPH02300A (ja) 1990-01-05
NO885389L (no) 1989-06-05
PT89121A (pt) 1989-12-29
FI885628L (fi) 1989-06-05

Similar Documents

Publication Publication Date Title
AU2635088A (en) Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
EP0188920A3 (en) Interleukin 1 and its derivative
IL86378A0 (en) Phosphinothricin-resistant gene
GB8724618D0 (en) Micropipette
EG19726A (en) Molluscicides
GB2207687B (en) Recording materials
JPS6456668A (en) Novel pyrazineamide compound and manufacture
JPS6419050A (en) Chemical intermediate and manufacture
PL270562A1 (en) Insecticidal and saprophyticidal specific
IE883606L (en) Immobilized interleukin 2
CS867987A1 (en) Zpusob pripravy 1 isokyanato 4 ehlorbenzenu
PL263661A1 (en) Can
HUT57654A (en) Writing materials
JPS6425789A (en) Substituted amidephophonate and amidephosphate
EP0297533A3 (en) Novel acetylpolyamine amidohydrolase
CS266487A1 (en) Zpusob pripravy 4 jodanilinu
CS262187A1 (en) Tricyklicke 4 substituovane 1 methyltetra hydrothiopyraniumjodidy
CS339587A1 (en) Thienotricyklicke 4 substituovane 1 methyltetrahydrothio pyraniumjodidy
CS26687A1 (en) Sposob pripravy vysokocisteho 2 propanolu
CS806887A1 (en) 11 11 87
CS26787A1 (en) Sposob pripravy vysokocisteho 2 propanolu
CS330887A1 (en) Triglyceridy 2 arylpropionovych kyselin
CS92687A1 (en) 2alkyltio 6 formamidobenzotiazoly
GB8704374D0 (en) Teaching pharmacokinetics
IE870720L (en) Molluscicides